$0.99-1.3%Nov 13 close
Reported results on November 12, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $14.2M | -100.00% |
| Profit | -$9.6M | -$1.7M | -461.88% |
| Profit per share | -$0.16 | -$0.03 | -433.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Spero Therapeutics, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Disease IgG4-related disease (IgG4-RD) is a rare, chronic, immune-mediated condition characterized by inflammation and fibrosis that can affect multiple organs, including the pancreas, kidneys, lungs, salivary and lacrimal glands, and lymph nodes. The pathogenesis of IgG4-RD is complex and is believed to involve dysregulation across multiple components of the immune system, including B cells, T cells and innate immune cells, including antigen-presenting cells, which interact to drive the inflammatory and fibrotic processes underlying the disease. The disease can cause progressive and potentially irreversible organ damage if not adequately controlled. These challenges underscore the need for additional targeted therapies that can provide durable disease control while reducing reliance on chronic immunosuppression.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Spero Therapeutics, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.